State medical regulators have filed additional complaints against a Houston doctor whose cancer treatments have incurred heavy criticism from health administrators and fellow physicians.
The Texas Medical Board submitted an expanded complaint earlier this month contending that Dr. Stanislaw Burzynski lures patients who are ineligible for his experimental drug and charges heavy fees before any consultation, among other charges.
Regulators also determined he acted unprofessionally and failed to meet state standards of care, according to the Houston Chronicle (http://bit.ly/UsW0Jg ).
An original complaint filed in January against the 70-year-old Burzynski was eight pages long but the expanded one filed July 8 covers 200 pages. It says in part that the board is authorized to take action against him for "unprofessional or dishonorable conduct that is likely to deceive or defraud the public or injure the public."
Burzynski's lawyer, Richard Jaffe, said the complaint was "outrageous" and is part of a vendetta by the board.
He said he plans at some point to present evidence that Burzynski's treatment works better than the current standard of care and "maybe that'll stop this process."
The federal Food and Drug Administration has given limited approval for Burzynski to move forward with clinical trials using his controversial anti-neoplaston drug, which is a synthesized version of human peptides found in blood and urine. The FDA had placed a partial hold on the trial, barring him from enrolling new patients after the 2012 death of a 6-year New Jersey boy.
He's fought with state and federal regulators over his drug for decades. A state hearing on the complaints against him isn't expected to be held until next year.
The Texas Medical Board is the only body that can invalidate a doctor's license, but the complaint doesn't indicate that is the board's intention with Burzynski. Board officials declined to comment.
Much of the new complaint provides details about Burzynski's treatment of patients, particularly seven whose standard of care was allegedly violated, according to the newspaper. It said Burzynski misled patients by promoting anti-neoplastons as "an attraction to bring patients to his medical practice when (he) was aware he could not legally include most in FDA-approved Phase 2 clinical trials."
Information from: Houston Chronicle, http://www.houstonchronicle.com